A dual GLP-1/GIP agonist, tirzepatide, has been developed for the treatment of T2D [77,78], while GIP antagonism, utilising a selective competitive inhibitor (GIP fragment GIP(3–30)NH2), has been examined in a pre-clinical setting for potential benefits in T2D [79]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.